As an example, identification of a heterozygous PGV in CHEK2 in a patient with a rare sarcoma could lead to a recommendation for a PARP inhibitor with an evidence level of m2B (based on evidence in prostate cancer, Table 2), especially when a somatic loss of heterozygosity and a single-base substitution signature 3 (SBS3, BRCAness) indicate a relevance of the CHEK2 variant for the tumor. This evidence concerns the gene CHEK2 and prostate cancer.